Circulating and tumor‑infiltrating myeloid‑derived suppressor cells in cervical carcinoma patients

Wu,Liangliang; Liu,Hongyu; Guo,Hongchuan; Wu,Qiong; Yu,Songyan; Qin,Yuanyuan; Wang,Gang; Wu,Qiyan; Zhang,Rong; Wang,Lingxiong; Zhang,Lijun; Liu,Chunxi; Jiao,Shunchang; Liu,Tianyi

doi:10.3892/ol.2018.8532

Circulating and tumor‑infiltrating myeloid‑derived suppressor cells in cervical carcinoma patients

Authors:
- Liangliang Wu
- Hongyu Liu
- Hongchuan Guo
- Qiong Wu
- Songyan Yu
- Yuanyuan Qin
- Gang Wang
- Qiyan Wu
- Rong Zhang
- Lingxiong Wang
- Lijun Zhang
- Chunxi Liu
- Shunchang Jiao
- Tianyi Liu
View Affiliations

Affiliations: Department of Oncology, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China, Department of Gynaecology and Obstetrics, Dongzhimen Hospital, Beijing 100700, P.R. China, Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Blood Transfusion, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba 277‑8577, Japan
Published online on: April 18, 2018 https://doi.org/10.3892/ol.2018.8532
Pages: 9507-9515

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myeloid‑derived suppressor cells (MDSCs) serve an immunosuppressive role in human tumors. Human Lin‑/low human leukocyte antigen‑antigen D related (HLA‑DR‑) cluster of differentiation (CD)‑11b+CD33+ MDSCs are closely linked with tumor staging, progression, clinical therapeutic efficacy and prognosis for various types of tumors. The present study employed multiparametric flow cytometry to measure the proportion of Lin‑/lowHLA‑DR‑CD11b+CD33+ MDSCs in the peripheral blood of 105 cervical cancer patients and 50 healthy subjects. The level of MDSC was higher in tumor patients than in the normal control group and this was closely associated with clinical staging. Further analysis of tumor‑infiltrating MDSCs was performed in 22 patients. The MDSC proportions in tumor tissue were significantly higher than those in the corresponding adjacent tissue. The phenotypic characteristics of Lin‑/lowHLA‑DR‑CD11b+CD33+ MDSCs were then evaluated and the results revealed that they express high CD13 and CD39, and low CD115, CD117, CD124 and programmed cell death ligand 1; they were also devoid of CD14, CD15 and CD66b. MDSCs and T‑cells from peripheral blood were sorted by flow cytometry for co‑culture experiments. Lin‑/lowHLA‑DR‑CD11b+CD33+ MDSCs from patients significantly inhibited the proliferation of CD4 and CD8 T‑cells. Furthermore, functional analysis verified that MDSCs from cervical cancer patients could inhibit interleukin‑2 and interferon‑γ production from T‑cells. In addition, the associations between peripheral circulating MDSCs and tumor infiltrating MDSCs, and tumor relapse and metastasis were analyzed. The number of peripheral MDSCs and MDSCs in tumor tissue were observed to be associated with relapse‑free survival. Thus, MDSCs in the peripheral blood and tumors of cervical cancer patients have a significant immunosuppressive effect, and are associated with cervical cancer staging and metastasis. These results suggest that targeting MDSCs may increase antitumor immunity and increase the efficacy of cervical cancer therapies.

View Figures

View References

1	Ho GY, Bierman R, Beardsley L, Chang CJ and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 338:423–428. 1998. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Trottier H and Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine. 24 Suppl 1:S1–S15. 2006. View Article : Google Scholar : PubMed/NCBI
4	Woodman CB, Collins SI and Young LS: The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 7:11–22. 2007. View Article : Google Scholar : PubMed/NCBI
5	Grabowska AK and Riemer AB: The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J. 6:249–256. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kanodia S, Fahey LM and Kast WM: Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 7:79–89. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kobayashi A, Weinberg V, Darragh T and Smith-McCune K: Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 1:412–420. 2008. View Article : Google Scholar : PubMed/NCBI
8	Piersma SJ: Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 4:361–375. 2011. View Article : Google Scholar : PubMed/NCBI
9	Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH and Fleuren GJ: Human leukocyte antigen class I, MHC class I chain-related molecule A and CD8+/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients? Clin Cancer Res. 14:2028–2035. 2008. View Article : Google Scholar : PubMed/NCBI
10	De Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH and Jordanova ES: Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer. 133:2884–2894. 2013.PubMed/NCBI
11	Gabrilovich DI, Ostrand-Rosenberg S and Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
12	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
13	Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, et al: A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 118:2254–2265. 2011. View Article : Google Scholar : PubMed/NCBI
14	Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
15	Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V and Mandruzzato S: Myeloid-derived suppressor cells in cancer patients: A clinical perspective. J Immunother. 35:107–115. 2012. View Article : Google Scholar : PubMed/NCBI
16	Greten TF, Manns MP and Korangy F: Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 11:802–807. 2011. View Article : Google Scholar : PubMed/NCBI
17	Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R and Ochoa AC: Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:1553–1560. 2009. View Article : Google Scholar : PubMed/NCBI
18	Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol. 166:678–689. 2001. View Article : Google Scholar : PubMed/NCBI
19	Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar : PubMed/NCBI
20	Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ and Ostrand-Rosenberg S: Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 57:1493–1504. 2008. View Article : Google Scholar : PubMed/NCBI
21	Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, et al: CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 186:1025–1036. 2012. View Article : Google Scholar : PubMed/NCBI
22	Huang A, Zhang B, Wang B, Zhang F, Fan KX and Guo YJ: Increased CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 62:1439–1451. 2013. View Article : Google Scholar : PubMed/NCBI
23	Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, Yancey D, Dahm P and Vieweg J: Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 14:8270–8278. 2008. View Article : Google Scholar : PubMed/NCBI
24	Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, et al: Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer. Breast Cancer Res Treat. 132:215–223. 2012. View Article : Google Scholar : PubMed/NCBI
25	Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA and Finke J: Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 13:591–599. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H and Zhao K: Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 8:e571142013. View Article : Google Scholar : PubMed/NCBI
27	Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 7:121502016. View Article : Google Scholar : PubMed/NCBI
28	Melani C, Chiodoni C, Forni G and Colombo MP: Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 102:2138–2145. 2003. View Article : Google Scholar : PubMed/NCBI
29	Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP and Zanovello P: Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 96:3838–3846. 2000.PubMed/NCBI
30	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
31	Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM and Kusmartsev S: Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 130:1109–1119. 2012. View Article : Google Scholar : PubMed/NCBI
32	Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al: HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 207:2439–2453. 2010. View Article : Google Scholar : PubMed/NCBI
33	Ghiringhelli F, Bruchard M, Chalmin F and Rébé C: Production of adenosine by ectonucleotidases: A key factor in tumor immunoescape. J Biomed Biotechnol. 2012:4737122012. View Article : Google Scholar : PubMed/NCBI
34	Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 204:1257–1265. 2007. View Article : Google Scholar : PubMed/NCBI
35	Bergamin LS, Braganhol E, Zanin RF, Edelweiss MI and Battastini AM: Ectonucleotidases in tumor cells and tumor-associated immune cells: An overview. J Biomed Biotechnol. 2012:9598482012. View Article : Google Scholar : PubMed/NCBI
36	Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, Dikov MM and Feoktistov I: Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol. 187:6120–6129. 2011. View Article : Google Scholar : PubMed/NCBI
37	Zou W and Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI